Treatment for stage 3 myeloma is typically divided into phases. The goal is to achieve a deep remission, meaning the cancer ...

Scientists say they may have finally found out why America's second most common blood cancer strikes a certain group of ...

On-chain investigator ZachXBT has brought to light a major crypto draining campaign that is affecting wallets across multiple EVM chains. According to an alert on ZachXBT’s Telegram channel, an ...

A new study from researchers with Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine and other top-tier cancer centers highlights the vital role that the immune ...

ALLENTOWN, Pa. (WPVI) -- A popular holiday lights display in Allentown will reopen to pedestrians on Monday night. This comes after police say vandals caused more than $100,000 in damage to "Lights in ...

"Medical Journeys" is a set of clinical resources reviewed by physicians, meant for the medical team as well as the patients they serve. Each episode of this journey through a disease state contains ...

Dec 10 (Reuters) - (This is an excerpt of the Health Rounds newsletter, where we present latest medical studies on Tuesdays and Thursdays. To receive the full newsletter in your inbox for free sign up ...

MSK cellular therapist Dr. Heather Landau led a phase 1 clinical trial showing CAR T cell therapy is effective against relapsed or resistant AL amyloidosis. “I’ve seen very sick patients have an ...

-- Company to host a live webcast event with an expert panel of clinicians during ASH -- REDWOOD CITY, Calif.--(BUSINESS WIRE)--Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagining cell ...

Treatment with an immune and cancer cell-targeting antibody therapy eradicates residual traces of the blood cell cancer multiple myeloma, according to interim results from a clinical trial conducted ...

Peter Voorhees, MD, discusses the AQUILA study's impact on treating patients with high-risk smoldering multiple myeloma, paving the way for new therapies. In an interview with Targeted Oncology, Peter ...